Lung Cancer News

Ivonescimab significantly improved PFS compared with pembrolizumab as first-line treatment of PD-L1-positive advanced non-small cell lung cancer, according to results of the HARMONi-2 trial.

Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable non-small cell lung cancer, according to a comparison of results from two randomized phase 3 trials.

Acceptance and utilization of lung cancer biomarker testing has increased in the past 6 years, but key barriers persist, according to survey results.

Patients with central airway obstruction are often treated by multiple clinicians from different specialties, leading to varied management of the patients, according to a press release.

Neoadjuvant atezolizumab prior to chemoradiation therapy exhibited promising activity for patients with unresectable stage III non-small cell lung cancer, according to results of a nonrandomized phase 2 study.

Two randomized phase 3 trials of pembrolizumab — one in lung cancer and one in skin cancer — have been discontinued due to lack of efficacy, according to the agent’s manufacturer.

A novel therapeutic approach stimulated new and existing T-cell responses among patients with melanoma or non-small cell lung cancer, according to results of a phase 1 trial.

Current evidence does not support lung cancer screening for never-smokers or former light smokers with a family history of lung cancer, according to a commentary in Journal of Thoracic Oncology.

A lung nodule sized 30 mm3 or greater was found in 42% of adults in Northern Europe who reported either never smoking or former smoking, according to results published in Radiology.

The FDA approved amivantamab-vmjw plus lazertinib as first-line treatment for certain adults with non-small cell lung cancer.